Search results for "tolerance"

showing 10 items of 956 documents

Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)

1990

• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms. ( Arch Intern Med. 1990;150:2401-2402)

Blood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousHypoglycemiaOctreotideRefractoryInternal medicineInternal MedicinemedicineHumansInsulinOral glucose toleranceSevere disorderGlucose tolerance testReactive hypoglycemiaC-Peptidemedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseHypoglycemiaSomatostatin AnaloguePostprandialEndocrinologyFoodbusinessArchives of Internal Medicine
researchProduct

One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency

2017

Purpose: In children, the plasma glucose value at 1 h (1hPG) during OGTT higher than 132.5 mg/dl is a predictor of alterations in glucose metabolism. We aimed to metabolically characterize GHD children according to 1hPG levels. Methods: Fifty-one GHD children (35 M, 16 F; mean age 8.6 years), grouped according to 1hPG, were evaluated at diagnosis and after 12 months of GH treatment (GHT) and compared with 50 matched controls at baseline. Auxological parameters, insulin-like growth factor-1 (IGF-1), glucose and insulin during OGTT, lipid profile, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and the insulin sensitivity index (ISI…

Blood GlucoseMalemedicine.medical_specialtyTime FactorsTime FactorEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyCarbohydrate metabolismSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceGH treatmentInternal medicineInsulin SecretionHumansInsulinMedicineChildDwarfism PituitaryGrowth hormoneGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryCholesterolInsulinCase-control studynutritional and metabolic diseasesGlucose Tolerance TestInsulin sensitivitymedicine.diseaseMetabolismEndocrinologychemistryCase-Control StudiesChild PreschoolMetabolomeFemaleInsulin ResistanceCase-Control StudiebusinessLipid profileHomeostasisHumanJournal of Endocrinological Investigation
researchProduct

Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione an…

2008

BACKGROUND AND PURPOSE Hypertension is known to be highly prevalent among patients with diabetes and associated with an increased risk of cardiovascular damage. In contrast, relatively few investigations have addressed the prevalence of diabetes among patients with hypertension. The purpose of the present study was to examine the prevalence of type 2 diabetes, the effectiveness of hypertension and diabetes control and the association with other cardiovascular risk factors and previous cardiovascular diseases in a cohort of patients with hypertension referred to 30 hospital outpatient clinics for the treatment of hypertension. METHODS AND PATIENTS Patients were considered as having diabetes …

Blood GlucoseMalemedicine.medical_specialtyhypertensionPhysiologyBlood Pressurediabetes; hypertension; prevalenceType 2 diabetesAmbulatory Care FacilitiesCohort Studieschemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusPrevalenceInternal MedicinemedicineHumansOutpatient clinicAgedCreatinineGlucose tolerance testDiabete di tipo 2 ipertensione arteriosamedicine.diagnostic_testdiabetesbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseasediabetes; hypertensionBlood pressureEndocrinologyDiabetes Mellitus Type 2ItalychemistryFemaleMicroalbuminuriaCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease.

1997

The minimum model modified by the administration of insulin provides an objective and relatively easily measured index of peripheral sensitivity to insulin which was significantly lower (p <0.02) in familial combined hyperlipidemia (FCH) with ischemic heart disease (IHD) than in FCH without IHD and in control subjects (1.2 +/- 0.6, 1.9 +/- 1.0, 2.9 +/- 1.2 x 10(-4) mU/L/ min, respectively). In patients with FCH, insulin resistance explains, at least in part, their metabolic alterations (hypertension, abnormal glucose tolerance, hyperinsulinemia) and elevated IHD.

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsHyperlipidemia Familial CombinedCoronary DiseaseDiseaseCoronary artery diseaseInsulin resistanceRisk FactorsInternal medicineHyperinsulinemiaMedicineHumansInsulinIn patientcardiovascular diseasesbusiness.industryInsulinGlucose Tolerance TestMiddle Agedmedicine.diseasePeripheralPedigreeEndocrinologyPhenotypeCardiologyInsulin ResistanceCardiology and Cardiovascular MedicinebusinessLipoproteinThe American journal of cardiology
researchProduct

Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats

2010

Abstract Mildronate is a cardioprotective drug, the mechanism of action of which is based on the regulation of l -carnitine concentration. We studied the metabolic effects of treatment with mildronate, metformin and a combination of the two in the Zucker rat model of obesity and impaired glucose tolerance. Zucker rats were p.o. treated daily with mildronate (200 mg/kg), metformin (300 mg/kg), and a combination of both drugs for 4 weeks. Weight gain and plasma metabolites reflecting glucose metabolism were measured. The expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ and target genes was measured in rat heart and liver tissues. Each treatment decreased the blood …

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentPeroxisome proliferator-activated receptorCarbohydrate metabolismImpaired glucose toleranceEatingInternal medicinemedicineAnimalsHypoglycemic AgentsInsulinPPAR alphaLactic AcidObesityRNA MessengerCarnitineCell NucleusPharmacologychemistry.chemical_classificationbusiness.industryMyocardiumInsulinBody WeightLipid Metabolismmedicine.diseaseMetforminRatsRats ZuckerMetforminPPAR gammaDrug CombinationsEndocrinologyGene Expression RegulationMechanism of actionchemistryCarnitine biosynthesismedicine.symptombusinessMethylhydrazinesmedicine.drugEuropean Journal of Pharmacology
researchProduct

The neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice

2019

International audience; Recent studies have shown that the hypothalamic neuropeptide 26RFa regulates glucose homeostasis by acting as an incretin, and increasing insulin sensitivity. In this study, we further characterized the role of the 26RFa/GPR103 peptidergic system in the global regulation of glucose homeostasis using a 26RFa receptor antagonist, and also assessed whether a dysfunction of the 26RFa/GPR103 system occurs in obese hyperglycemic mice. Firstly, we demonstrate that administration of the GPR103 antagonist reduces the global glucose-induced incretin effect and insulin sensitivity whereas, conversely, administration of exogenous 26RFa attenuates glucose-induced hyperglycemia. U…

Blood GlucoseMaleobesityPhysiologyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]RegulatorMice Obese26RFaMice0302 clinical medicineGlucose homeostasisHomeostasisInsulinglucoseComputingMilieux_MISCELLANEOUSCells Cultured0303 health sciencesdiabetesChemistryincretin[SDV] Life Sciences [q-bio]obésitéAlimentation et NutritionCarbohydrate Metabolismdiabètemedicine.medical_specialtyNeuropeptideIncretin030209 endocrinology & metabolism03 medical and health sciencesPhysiology (medical)Diabetes mellitusInternal medicinemedicineAnimalsHumansglucose homeostasisFood and Nutrition030304 developmental biologyhoméostasieNeuropeptidesIncreasing insulinQRFPNeurosciencesGlucose Tolerance Testmedicine.diseaseMice Inbred C57BLEndocrinologyHyperglycemiaNeurons and Cognitionincretin;glucose homeostasis;26RFa;diabetes;obesity
researchProduct

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

2017

Abstract Although the better management of rheumatoid arthritis (RA) has significantly improved the long-term outcome of affected patients, a significant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conflicting results are still av…

Blood GlucoseMalerheumatoid arthritisTime FactorsCross-sectional studyType 2 diabetesAdrenal Cortex HormoneBody Mass IndexArthritis Rheumatoid0302 clinical medicineimpaired fasting glucoseAdrenal Cortex HormonesRisk FactorsRheumatoidCardiovascular DiseasePrevalence030212 general & internal medicineMedicine (all)Diabetes MellituGeneral MedicineMiddle AgedC-Reactive ProteinCholesterolcardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes;Cardiovascular DiseasesCohortHypertensionFemaletype 2 diabetesCase-Control Studiecardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes; Adrenal Cortex Hormones; Adult; Aged; Arthritis Rheumatoid; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Middle Aged; Prevalence; Risk Factors; Time Factors; Medicine (all)Type 2Research ArticleArthritiHumanAdultcardiovascular riskmedicine.medical_specialtyTime FactorObservational StudyNO03 medical and health sciencesInternal medicineDiabetes mellitusGlucose Intolerancemedicinecardiovascular risk impaired fasting glucose inflammation rheumatoid arthritis type 2 diabetesHumansAged030203 arthritis & rheumatologyCross-Sectional Studietype 2 diabetebusiness.industryRisk Factor6900Case-control studyrheumatoid arthritimedicine.diseaseImpaired fasting glucoseSettore MED/16 - ReumatologiaCross-Sectional StudiesDiabetes Mellitus Type 2inflammationCase-Control StudiesMetabolic syndromebusinessBody mass index
researchProduct

Associations of resting and peak fat oxidation with sex hormone profile and blood glucose control in middle-aged women.

2022

Background and Aims Menopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO with glucose regulation. Method and Results We measured RFO and PFO of 42 women (age 52–58 years) with indirect calorimetry. Seven participants were pre- or perimenopausal, 26 were postmenopausal, and nine were postmenopausal hormone therapy users. Serum estradiol (E2), follicle-stimulating hormone, progesterone, and testosterone levels were quantified with immunoassays. Insulin sensitivity (Matsuda index) and glucose tolerance (…

Blood GlucoseestradioliNutrition and Dieteticsvaihdevuodetglucose toleranceEndocrinology Diabetes and MetabolismhapettuminenmenopauseMedicine (miscellaneous)fat oxidationGlycemic ControlMiddle Agedinsuliiniresistenssirasva-aineenvaihduntahormonaaliset tekijätGlucoseglukoosi-intoleranssiestradiolBody Compositioninsulin sensitivityHumansFemaleInsulin ResistanceCardiology and Cardiovascular MedicineGonadal Steroid HormonesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month re…

2018

OBJECTIVE Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement of anthropometric and metabolic parameters. The aim of the study was to evaluate the effects of DR-HC on insulin secretion and sensitivity and cardiometabolic risk, indirectly expressed by the visceral adiposity index (VAI). DESIGN AND PATIENTS Retrospective analysis of 49 patients, 13 with primary and 36 with secondary adrenal insufficiency (AI), respectively, on conventional glucocorticoid treatment at baseline and switched to DR-HC for 36 months. Overall, 24 patients had AI-pre-diabetes (impaired fasting glucose, impaired glucose tolerance and the combination), and 25 had AI-…

Blood Glucoseinsulin secretionmedicine.medical_specialtyWaistHydrocortisoneEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaImpaired glucose tolerancePrediabetic State03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusGlucose IntolerancemedicineAdrenal insufficiencyHumansplenadrenPrediabetesGlucocorticoidsHydrocortisoneRetrospective Studiesbusiness.industryAdrenal insufficiency; diabetes; dual-release hydrocortisone; insulin secretion; plenadren; Endocrinology Diabetes and MetabolismFastingImpaired fasting glucosemedicine.diseaseEndocrinologydiabetedual-release hydrocortisoneInsulin ResistanceWaist CircumferencebusinessGlucocorticoidmedicine.drugAdrenal InsufficiencyClinical endocrinology
researchProduct

Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysi…

2021

There is a large and growing body of literature focusing on the use of oral magnesium (Mg) supplementation for improving glucose metabolism in people with or at risk of diabetes. We therefore aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes, compared with a placebo. Several databases were searched investigating the effect of oral Mg supplementation vs placebo in patients with diabetes or conditions at high risk of diabetes. Data were reported as standardized mean differences (SMDs) with their 95% confidence intervals (CIs) using follow-up data of glucose and insulin-sensitivity …

Blood Glucosemedicine.medical_specialtyMagnesium supplementationCarbohydrate metabolismmagnesiumPlaceboGastroenterologyArticlelaw.inventionDouble blindRandomized controlled trialDouble-Blind MethodlawDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansTX341-641glucoseRandomized Controlled Trials as TopicNutrition and Dieteticsdiabetesbusiness.industryNutrition. Foods and food supplyGlucose Tolerance Testmedicine.diseaseConfidence intervalmeta-analysisTreatment OutcomediabeteMeta-analysisDietary SupplementsInsulin ResistancebusinessFood ScienceNutrients
researchProduct